Curemark

Curemark is a clinical-stage biotech pioneering a novel approach to neurological disorders by targeting underlying enzyme deficiencies, particularly in protein digestion. The company's lead asset, CM-AT for Autism Spectrum Disorder, has completed pivotal studies and represents a potential first-in-class treatment. Curemark's proprietary platform, which links pancreatic enzyme function to neurotransmitter production, also supports a broader pipeline targeting ADHD, addiction, Parkinson's, and schizophrenia. As a private company, its near-term success hinges on advancing CM-AT towards regulatory approval and commercialization.

Proprietary enzyme replacement technology targeting pancreatic enzyme deficiencies to correct amino acid imbalances and subsequent neurotransmitter dysfunction in neurological diseases. Includes a novel drug delivery system for optimal intestinal release.

In autism, Curemark's CM-AT is mechanistically unique; competitors focus on symptomatic treatments for irritability (e.g., risperidone, aripiprazole) or are developing therapies targeting different pathways. In broader neurology, it faces competition from large pharma and biotech firms with extensive R&D resources across all pipeline indications.